aBLA Filing Intelligence & Biosimilar Opportunity

Adbry

Tralokinumab-Ldrm

Dermatologic

Injection Injectable

Approval Date

27-Dec-21

Data Exclusivity Expiry

27-Dec-25

Market Exclusivity Expiry

27-Dec-33

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Tralokinumab-Ldrm

Innovator

LEO PHARMA INC.

Dosage Form

Injection Injectable

Strength

150 mg/mL

Therapeutic Category

Dermatologic

Usage

To treat moderate-to-severe atopic dermatitis

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.